SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Ardelyx Completes Enrollment in Phase 3 Ibsrela Trial

Ardelyx said it has fully enrolled patients in its Phase 3 Ibsrela trial for chronic idiopathic constipation.

ARDX

Related stories